51 related articles for article (PubMed ID: 11368209)
1. The serum soluble HLA-DR antigens as a predictive marker of the response to interferon-alpha treatment in patients with chronic hepatitis C.
Hosoi K; Hagihara M; Kagawa T; Watanabe N; Matsuzaki S
Tokai J Exp Clin Med; 2000 Oct; 25(3):117-24. PubMed ID: 11368209
[TBL] [Abstract][Full Text] [Related]
2. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis C in the advanced adult and elderly subjects.
Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
[TBL] [Abstract][Full Text] [Related]
4. Changes of hepatic vitronectin levels in patients with chronic hepatitis C treated with interferon alpha.
Yamada S; Suou T; Kawasaki H; Horie Y; Nagami M; Yashima S; Sugihara C; Tanaka H
Res Commun Mol Pathol Pharmacol; 1999; 104(3):253-63. PubMed ID: 10741376
[TBL] [Abstract][Full Text] [Related]
5. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.
Ulsenheimer A; Gerlach JT; Jung MC; Gruener N; Wächtler M; Backmund M; Santantonio T; Schraut W; Heeg MH; Schirren CA; Zachoval R; Pape GR; Diepolder HM
Hepatology; 2005 Mar; 41(3):643-51. PubMed ID: 15726647
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.
Maruyama S; Hirayama C; Horie Y; Yorozu K; Maeda K; Inoue M; Fujii Y; Umeki K; Koda M
Hepatogastroenterology; 2007 Mar; 54(74):493-8. PubMed ID: 17523306
[TBL] [Abstract][Full Text] [Related]
7. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
8. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
[TBL] [Abstract][Full Text] [Related]
9. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment.
Carrera G; Paternain JL; Carrere N; Folch J; Courtade-Saïdi M; Orfila C; Vinel JP; Alric L; Pipy B
Am J Gastroenterol; 2003 May; 98(5):1142-9. PubMed ID: 12809840
[TBL] [Abstract][Full Text] [Related]
10. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy.
Hamamoto S; Uchida Y; Wada T; Moritani M; Sato S; Hamamoto N; Ishihara S; Watanabe M; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):204-8. PubMed ID: 15683422
[TBL] [Abstract][Full Text] [Related]
12. [Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin].
Jiao J; Wang JB
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):620-2. PubMed ID: 14572343
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy.
Dejica D; Grigorescu M; Dejica V; Radu C; Neculoiu D
Rom J Gastroenterol; 2002 Dec; 11(4):277-83. PubMed ID: 12532197
[TBL] [Abstract][Full Text] [Related]
14. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C.
Hokari A; Zeniya M; Esumi H; Ishikawa T; Kurasima Y; Toda G
J Infect; 2005 Jul; 51(1):47-53. PubMed ID: 15979491
[TBL] [Abstract][Full Text] [Related]
15. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
16. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.
Muto H; Tanaka E; Matsumoto A; Yoshizawa K; Kiyosawa K;
J Gastroenterol; 2004 Jul; 39(7):674-80. PubMed ID: 15293139
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis.
Berres ML; Schnyder B; Yagmur E; Inglis B; Stanzel S; Tischendorf JJ; Koch A; Winograd R; Trautwein C; Wasmuth HE
Liver Int; 2009 Apr; 29(4):536-43. PubMed ID: 18795898
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
Ueno T; Ide T; Hashimoto O; Uchimura Y; Torimura T; Kumashiro R; Inuzuka S; Sata M
Hepatogastroenterology; 2001; 48(40):1124-8. PubMed ID: 11490815
[TBL] [Abstract][Full Text] [Related]
19. Serum soluble HLA-DR antigens in autoimmune hepatitis.
Hagihara M; Hosoi K; Kagawa T; Gansuvd B; Munkhbat B; Shimura T; Watanabe N; Matsuzaki S; Tsuji K
Autoimmunity; 1999 Oct; 31(2):85-93. PubMed ID: 10680746
[TBL] [Abstract][Full Text] [Related]
20. Association between human leukocyte antigen (HLA) and interferon- induced thyroid diseases in four patients with HCV-related chronic hepatitis.
Labbadia G; Martocchia A; Mammarella A; Paoletti V; Rocco A; Benvenuto R; Antonella P; Rosaria D; Trabace S; Musca A; Falaschi P
Neuro Endocrinol Lett; 2005 Apr; 26(2):109-12. PubMed ID: 15855880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
